Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
15.89
+0.68 (4.47%)
At close: Aug 13, 2025, 4:00 PM
15.61
-0.28 (-1.76%)
Pre-market: Aug 14, 2025, 8:33 AM EDT
Immunovant Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Immunovant stock ranges from a low of $17 to a high of $53. The average analyst price target of $35.88 forecasts a 125.80% increase in the stock price over the next year.
Price Target: $35.88 (+125.80%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Immunovant stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 3 | 3 | 3 | 3 | 3 |
| Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Hold | 1 | 2 | 2 | 2 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 10 | 10 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $40 → $37 | Buy | Maintains | $40 → $37 | +132.85% | Aug 12, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $33 → $30 | Strong Buy | Maintains | $33 → $30 | +88.80% | Aug 12, 2025 |
| UBS | UBS | Hold Maintains $17 → $18 | Hold | Maintains | $17 → $18 | +13.28% | Jul 28, 2025 |
| UBS | UBS | Strong Buy → Hold Downgrades $38 → $17 | Strong Buy → Hold | Downgrades | $38 → $17 | +6.99% | Apr 22, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Mar 20, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
79.77M
EPS This Year
-2.96
from -2.73
EPS Next Year
-3.01
from -2.96
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | 524.6M | 526.7M | ||
| Avg | n/a | 79.8M | 208.1M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | 560.3% | ||
| Avg | - | - | 160.9% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -2.64 | -1.45 | -2.27 | ||
| Avg | -2.96 | -3.01 | -2.92 | ||
| Low | -3.40 | -3.90 | -4.15 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.